ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.50 Average PT from Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $7.50.

A number of research firms have weighed in on PRQR. Chardan Capital cut their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, June 26th. Bank of America initiated coverage on ProQR Therapeutics in a research note on Thursday, August 20th. They issued a “buy” rating and a $8.00 price target for the company. JonesTrading lowered their price target on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Finally, Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Insiders Place Their Bets

In related news, CEO Boer Daniel Anton De acquired 150,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were acquired at an average cost of $1.74 per share, with a total value of $261,000.00. Following the completion of the acquisition, the chief executive officer directly owned 300,000 shares in the company, valued at approximately $522,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bart Filius bought 150,000 shares of the company’s stock in a transaction dated Friday, July 17th. The stock was bought at an average price of $1.72 per share, for a total transaction of $258,000.00. Following the transaction, the director owned 300,000 shares of the company’s stock, valued at approximately $516,000. This trade represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 600,000 shares of company stock valued at $988,500 over the last 90 days. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ProQR Therapeutics

Several large investors have recently bought and sold shares of PRQR. Privium Fund Management B.V. raised its holdings in shares of ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after acquiring an additional 359,475 shares during the last quarter. Ikarian Capital LLC increased its position in shares of ProQR Therapeutics by 67.2% during the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after purchasing an additional 600,000 shares in the last quarter. Citadel Advisors LLC raised its stake in ProQR Therapeutics by 73.2% in the 3rd quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after purchasing an additional 277,749 shares during the last quarter. Walleye Capital LLC raised its stake in ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 15,744 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in ProQR Therapeutics by 80.8% in the 4th quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock valued at $879,000 after purchasing an additional 194,369 shares in the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Trading Up 1.4%

ProQR Therapeutics stock opened at $2.15 on Friday. The firm has a market cap of $226.52 million, a PE ratio of -4.67 and a beta of 0.06. ProQR Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.10. The stock’s 50 day simple moving average is $1.89 and its two-hundred day simple moving average is $1.72.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.04. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. The firm had revenue of $10.00 million during the quarter, compared to analyst estimates of $4.56 million. On average, equities research analysts forecast that ProQR Therapeutics will post -0.45 EPS for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.